JP Morgan Raises Natera (NTRA) Price Target to $460

JP Morgan has reiterated its Overweight rating on Natera with a price target of $460, a 16.46% upside from the current price.

By EarningsIQ Research Desk · Published Oct 15, 2026, 9:18 PM EDT · Updated Oct 16, 2026, 2:15 PM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

JP Morgan raised its price target on Natera, Inc. ($NTRA) to $460 from $360 on October 14, 2026, and rates the stock "Overweight".

Since the rating, $NTRA is down 0.3% to date (from the $394.75 close on Oct 14, 2026).

NTRA Natera, Inc.

$393.44 +71.93% year to date

Daily close · Oct 16, 2026

Key Points

On October 14, 2026, JP Morgan reiterated its Overweight rating on Natera, Inc. (NTRA) with a new price target of $460, up from $360.
JP Morgan's $460 price target implies 16.46% upside from Natera, Inc.'s ($NTRA) current $394.99 share price.
As of October 16, 2026, Natera's shares were recently trading around $394.99, which is about 14.1% below JP Morgan's target.
Natera reported trailing twelve-month revenue of approximately $2.71 billion and has a negative net margin of 7.1%.

Get $NTRA trade alerts by text

We text you when insiders, Congress or big funds trade $NTRA. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Natera, Inc. alert may contain errors. Disclosures

JP Morgan has reiterated its Overweight rating on Natera, Inc. (NTRA) with a price target of $460 on October 14, 2026. This is an increase from the previous target of $360. The firm believes in the company's growth potential despite recent market challenges.

Analyst rating track record

JP Morgan vs. the S&P 500

YTD return -1.44% hypothetical

All-time return -1.44% S&P 500 +0.45%

vs. S&P 500 -1.89% behind the index

Hypothetical returns from JP Morgan's disclosed trades, not real profit or advice. How we model this.

Other Institutional Activity in Natera, Inc.

Natera has seen varied activity from other institutional investors. JPMorgan Chase & Co. reduced its holdings by 520,718 shares, bringing its total to 12,865,346 shares valued at about $5.06 billion. BlackRock Inc. slightly increased its stake by 237,042 shares, totaling 10,914,608 shares worth approximately $4.29 billion. Meanwhile, Price (T. Rowe) Associates Inc. cut its position by 3,163,268 shares, ending with 9,021,895 shares valued at around $3.55 billion. Vanguard Capital Management LLC also added 219,904 shares, resulting in a total of 6,228,216 shares worth about $2.45 billion.

Natera, Inc. Stock Down 2.4%

Natera's shares were recently trading around $394.99 as of October 16, 2026. This price is about 14.1% below JP Morgan's price target of $460. The stock's performance is notable as it navigates through a challenging market, having reported a revenue growth of 37.7% year-over-year.

12-month forecast

$NTRA price target

Natera, Inc. daily closes and this analyst's $460 target. Not advice.

Recent Earnings

Natera reported trailing twelve-month revenue of approximately $2.71 billion but has a negative net margin of 7.1%. The company is scheduled to announce its next earnings on November 5, 2026, which investors will be watching closely for insights into its financial health.

Insider Buying and Selling at Natera, Inc.

Recent insider selling at Natera includes Chief Executive Officer Steven Leonard Chapman, who sold 1,698 shares at an average price of $320.99 on September 1, 2026, totaling about $545,041. Other notable sales include Officer Solomon Moshkevich, who sold 18,160 shares on September 2, 2026, and Officer and Director Matthew Rabinowitz, who sold 50,000 shares on September 11, 2026, followed by another sale of 102,000 shares on September 15, 2026, with total values of about $5.92 million and $16.40 million respectively.

Analysts Set New Price Targets

On October 14, 2026, JP Morgan maintained its Overweight rating on Natera with a new price target of $460, up from $360. Earlier, Citigroup also maintained its Buy rating with a target of $480, while Barclays kept its Overweight rating, boosting its target to $475. Morgan Stanley and TD Cowen also maintained Overweight ratings with targets of $435 and $480 respectively.

About Natera, Inc.

Natera, Inc. is a diagnostics company based in Austin, Texas. It specializes in developing molecular testing services, including tests for cancer recurrence monitoring and hereditary cancer screening. The company's innovative products like Signatera and Latitude aim to improve patient outcomes in oncology. This focus on advanced diagnostics is crucial as the company continues to expand its market presence.

Bottom Line

Investors should keep an eye on Natera's upcoming earnings report on November 5, 2026, which could provide further insights into the company's performance. With JP Morgan reiterating its Overweight rating and raising its price target, market watchers will be interested to see how Natera performs in the coming months.